Immunogenicity of CAR-T Cell Therapeutics: Evidence, Mechanism and Mitigation

Chimeric antigen receptor T cell (CAR-T) therapy demonstrated remarkable success in long-term remission of cancers and other autoimmune diseases. Currently, six products (Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, and Carvykti) are approved by the US-FDA for treatment of a few hematological mali...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Aalia N., Chowdhury, Ambalika, Karulkar, Atharva, Jaiswal, Ankesh Kumar, Banik, Ankit, Asija, Sweety, Purwar, Rahul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169153/
https://www.ncbi.nlm.nih.gov/pubmed/35677038
http://dx.doi.org/10.3389/fimmu.2022.886546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169153/
https://www.ncbi.nlm.nih.gov/pubmed/35677038
http://dx.doi.org/10.3389/fimmu.2022.886546

Ejemplares similares